The mechanism involved in the envelope glycoprotein gp120-induced Th2 response to Cryptococcus neoformans was investigated. Peripheral blood mononuclear cells (PBMC) from healthy donors were treated with human immunodeficiency virus gp120 and an encapsulated or acapsular strain of C. neoformans in the presence or absence of glucuronoxylomannan, the major capsular polysaccharide. gp120 inhibited early and late production of interleukin (IL)-12 by PBMC. This reduction paralleled IL-10 induction and inhibited translocation of CD40 to the surface of monocytes. Flow cytometric analysis revealed that gp120 downregulated the expression of IL-12 receptor b2 subunit on T cells responding to C. neoformans. Because the IL-12/IL-12 receptor b2 subunit pathway is critical for the Th1 differentiation process, underexpression demonstrates that gp120 contributes to Th2 bias. Exogenous IL-12 added simultaneously with gp120 up-regulated interferon-g secretion and limited IL-4 production. These results suggest that gp120 limits the Th1 response to C. neoformans and that exogenous IL-12 could offset this effect.
Interleukin-12 Counterbalances the Deleterious Effect of Human
Recently, we demonstrated that gp120 exerts an antiproliferative effect on T cells responding to C. neoformans and promotes the emergence of a Th2-dominant response [11] . In particular, T cells cocultured with cryptococci-laden monocytes in the presence of gp120 displayed enhanced interleukin (IL)-4 secretion and almost complete abrogation of interferon (IFN)-g production relative to the levels of cytokine secretion observed in the absence of gp120 [11] . Analysis of the intracellular levels of these cytokines revealed that gp120 regulates the synthesis of IL-4 and IFN-g [11] .
Studies have shown that polarization of human T cells to Th1 or Th2 is regulated primarily by IL-12 production by antigenpresenting cells and IL-4 production by T cells [12] . In addition, a defect in IL-12 production during human immunodeficiency virus (HIV) infection [13] and involvement of gp120 as an inhibitor of IL-12 secretion have been observed [14] .
In a previous study, we demonstrated a biphasic pattern of IL-12 production by human monocytes exposed to C. neoformans. During the first phase, IL-12 secretion is dependent on the direct effect of fungal insult; the second phase is characterized by secretion of IL-12 that is dependent on the presence of IFN-g and ligation of CD40 molecules on monocytes, with CD40 ligand expressed on T cells [15] .
The purpose of this study was to examine the influence of gp120 on C. neoformans-induced IL-12 production, the influence of gp120 on early-and late-phase IL-12 secretion in response to C. neoformans, the mechanisms involved in gp120-induced IL-12 production, and whether and to what extent the addition of recombinant human IL-12 is able to reverse the gp120-induced Th2-dominant response to C. neoformans.
Materials and Methods
Reagents and media. RPMI 1640 with glutamine and fetal calf serum (FCS) were obtained from Gibco BRL. Human serum type AB was purchased from Sigma. HIV-1 recombinant gp120 (strain LAI) was obtained from a mammalian (CHO) expression system (Intracel) and had been used previously in studies that provided the background for the present set of experiments [11, 16] . gp41 was purchased from DuPont NEN Research Products. Mouse monoclonal anti-human CD40 (IgG1; catalog no. 189.020), Rphycoerythrin-conjugated mouse monoclonal anti-human CD14 (IgG2; catalog no. 163-050), and mouse monoclonal anti-human CD4 (IgG1; catalog no. 147.020) were obtained from Ancell. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-mouse IgG (F[ab ] 2 ; catalog no. F2883) and an irrelevant mouse monoclonal antibody (IgG1; catalog no. M5284) were purchased from Sigma. Glucuronoxylomannan (GXM), the major capsular polysaccharide of C. neoformans, was isolated from culture supernatant fluid of serotype A strain CN6 by differential precipitation with ethanol and cetyl-trimethyl-ammonium bromide [17] . Human recombinant IL-12 was from the Genetic Institute. All media and buffers used in this study were tested for endotoxin contamination by limulus amebocyte lysate assay (Sigma), which has a sensitivity of ∼0.05-0.1 ng/mL Escherichia coli lipopolysaccharide. All tested media and buffers were negative.
Isolation and culture of peripheral blood monocytes. Heparinized venous blood was obtained from healthy volunteers and was diluted with RPMI 1640. Peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation over Ficoll-Paque Plus (Pharmacia Biotech) [18] . PBMC were recovered, were washed twice in RPMI 1640 supplemented with 5% FCS, penicillin (100 U/mL), and streptomycin (100 mg/mL), were plated into cell culture petri dishes (Nunc), and were incubated for 1 h at a concentration of 2-/mL. Nonadherent cells were re-6 3 ϫ 10 moved by washing the dishes 3-5 times with prewarmed RPMI 1640 medium. Adherent cells (peripheral blood monocytes) were recovered by means of a cell scraper (Falcon), were washed twice, and were suspended in RPMI 1640 supplemented with 10% human serum, penicillin (100 U/mL), and streptomycin (100 mg/mL). The harvested cells were 95%-98% esterase positive and 198% viable, as evaluated by trypan blue dye exclusion test. Nonadherent cells were E-rosetted as described elsewhere [19] . [20, 21] . C. neoformans 3168 is a heavily encapsulated serotype A strain (obtained from National Collection of Pathogenic Fungi [NCPF]; NCPF 3168). The cultures were maintained by serial passage on Sabouraud agar (BioMérieux). Log-phase yeasts were harvested by suspending a single colony in RPMI 1640, were washed twice with saline, were counted on a hemocytometer (Sigma), and were adjusted to the desired concentration in RPMI. All yeasts were killed before use by heating at 60ЊC for 30 min.
Flow cytometry analysis of surface and intracellular CD40. Surface molecule expression was quantified by flow cytometry after various times of culture. Monocytes ( ) were suspended in 6 1 ϫ 10 supplemented RPMI in polypropylene tubes and stimulated with encapsulated or acapsular strains of C. neoformans at an effector :target ratio of 1:2 or with GXM (250 mg/mL) or the acapsular strain plus GXM (250 mg/mL). GXM alone or in combination with the acapsular strain was added at the time of C. neoformans treatment, in the presence or absence of gp120 (500 ng/mL), and was incubated for different times. The effector:target ratio of 1:2 was used because our previous experiments found that this ratio was optimal for cytokine response and did not differ appreciably from the 1:15 or 1:10 ratio. In contrast, an inhibitory effect on cytokine production was found at an effector:target ratio 11:20. The dose of 250 mg/mL GXM was chosen on the basis of previous experiments, in which 250 mg/mL gave the best inhibitory effect, which was comparable to that obtained with 500 mg/mL. A lower dose (25 mg/mL) was less effective. As a positive control, peripheral blood monocytes were stimulated with IFN-g (5 ng/mL) plus lipopolysaccharide (10 mg/mL). After incubation at 37ЊC in the presence of 5% CO 2 , the cells were collected by centrifugation, fixed in 2% paraformaldehyde in PBS, washed twice in PBS containing 0.5% bovine serum albumin and 0.1% sodium azide, and mixed with mouse anti-human CD40. After 30 min of incubation on ice, the cells were washed twice, and the second antibody, FITC-conjugated anti-mouse IgG, was added. Monocytes were labeled with R-phycoerythrin-conjugated mouse monoclonal anti-human CD14, and 2-color analysis was done by use of a flow cytometer (FACScan; Becton Dickinson). The mean fluorescence of labeled cells was determined by use of logarithmic-scale histograms. Autofluorescence was assessed with untreated cells. An irrelevant FITC-conjugated isotype-matched antibody was used as a negative control in each experiment.
For determination of the intracellular pool of CD40, after 18 h of incubation, the cells were resuspended, were washed in PBS plus 0.5 mM EDTA, and were fixed at room temperature for 10 min with 2% paraformaldehyde. Cells were permeabilized for 10 min with HEPES-buffered PBS containing 0.1% saponin (Sigma) and were stained with mouse anti-human CD40, FITC-conjugated antimouse IgG in HEPES-buffered PBS containing 0.1% saponin and 5% FCS, and then phycoerythrin-conjugated mouse anti-human CD14.
Flow cytometry analysis of surface IL-12b receptor. PBMC (1 or /mL) were stimulated with C. neoformans 6995 in the 6 5 ϫ 10 presence or absence of gp120 (500 ng/mL) for 5 days. After incubation, cells (3- ) from each sample were incubated with 5 5 ϫ 10 5 mg/mL rat anti-human IL-12 receptor b2 subunit (IL-12Rb2; provided by F. Sinigaglia, Roche Milano, Milan, Italy), followed by incubation with FITC-conjugated anti-rat IgG (Sigma). Control samples were stained with the secondary antibody only. After 2 additional washes, cells were analyzed with a FACScan.
Determination of IL-12, IL-10, IL-4, and IFN-g production. PBMC (
in the case of IL-12, IL-10, and IFN-g; i n 6 7 5 ϫ 10 2 ϫ 10 the case of IL-4) were stimulated with gp120 (500 ng/mL) in the presence or absence of encapsulated or acapsular C. neoformans or with GXM (250 mg/mL) or the acapsular strain plus GXM (250 mg/ mL). GXM alone or in combination with the acapsular strain was added at the time of C. neoformans treatment. Supernatants were recovered after incubation for various times that were determined by individual experimental protocols and were stored at Ϫ80ЊC. Cytokine levels in culture supernatants were measured with an ELISA kit for human IL-4 (Endogen), IL-10 (Endogen), IL-12 (Biosource International), and human IFN-g (Euroclone). The antiserum for IFN-g is specific for this lymphokine, showing no apparent crossreactivity with human IL-1a, -1b, or IL-2 through -11; macrophage, granulocyte, or granulocyte-macrophage colony-stimulating factors; tumor necrosis factor (TNF)-a or TNF-b; or stem cell factor. The minimum detectable dose of IFN-g was 1-3 pg/mL. The antiserum for IL-4 was specific for this cytokine, showing no apparent crossreactivity with human IL-2, IL-6, or IL-10, IFN-g, granulocyte-macrophage colony-stimulating factor, TNF-a or TNF-b, or mouse IL-4. The IL-4 ELISA kit detected !2 pg/mL human IL-4. The antiserum for IL-10 was specific for this cytokine, showing no apparent crossreactivity with human IL-1a, -2, -3, -4, -6, -7, or -8 or TNF-a or TNF-b. The IL-10 ELISA kit detected !3 pg/mL human IL-10. The antiserum for IL-12 was specific for this cytokine, showing no apparent cross-reactivity with human IL-1b, -2, -3, -4, -5, -7, -8, -10, -13, or -15, granulocyte-macrophage colony-stimulating factor, TNF-a, stem cell factor, or IFN-g. The minimum detectable dose of human IL-12 was !0.8 pg/mL.
Statistical analysis. Statistical significance was determined by use of Student's paired t test.
Results
An initial experiment evaluated the effect of gp120 on the early (T cell-independent) and late (T cell-dependent) secretion of IL-12 in response to stimulation with C. neoformans [15] . Addition of gp120 suppressed early (day 2) IL-12 secretion in response to the encapsulated strain and late (day 7) IL-12 secretion in response to the acapsular and encapsulated strains (figure 1). That IL-12 inhibition was dependent on effective ligation and internalization of gp120 was suggested by the fact that an antibody to CD4 (2 mg/mL), added 1 h before gp120 addition, completely abrogated gp120 down-regulation of IL-12 production (not shown). A potential effect of Fc involvement in the anti-CD4 effect is unlikely, because the addition of an unrelated antibody at 2 mg/mL did not affect IL-12 production by unstimulated or C. neoformans-stimulated cells. As a further control, gp41 was used in place of gp120 because, unlike gp120, it does not link CD4 and is used exclusively to promote the fusion of HIV. Results done with gp41 were similar to results obtained with gp120-untreated cells (not shown). The downregulatory effect of gp120 on early induction of IL-12 was also observed when purified monocytes were used in place of PBMC. It should be noted that the size of the capsule did not influence the amount of IL-12 produced (figure 1). Addition of purified GXM to acapsular cryptococci results in binding of the GXM to the acapsular cells and experimental creation of cells that behave in many ways like encapsulated yeast cells [22] . When GXM and acapsular cryptococci were used in the experimental system, a similar suppressive action on the part of gp120 was observed; however, the magnitude of both the level of IL-12 secretion and the suppressive effect of gp120 was intermediate between those observed for acapsular and encapsulated cells ( figure 1) .
Stimulation of CD40 expression could provide a positive signal for IL-12 production in our experimental system [15] ; consequently, we examined the possibility that gp120 could inhibit IL-12 via CD40 modulation. Experiments were done to determine CD40 expression on monocytes treated with gp120 and stimulated with C. neoformans. The results (figure 2) show an increase in expression of CD40 on monocytes treated with encapsulated cryptococci or with purified GXM. This increased expression of CD40 was significantly down-regulated if gp120 was incorporated into the incubation mixture.
The mechanism for down-regulation of CD40 was investigated in an experiment in which total CD40 (staining for CD40 by use of permeabilized cells), surface CD40 (staining for CD40 by use of nonpermeabilized cells), or intracellular CD40 (total minus surface CD40) was determined. The results showed that the intracellular pool of CD40 was unchanged or slightly increased in cells treated with gp120, compared with that in untreated cells ( figure 3 ). The increase in intracellular CD40 in gp120-treated cells was most apparent in cells stimulated with encapsulated cryptococci or cells stimulated with acapsular cryptococci in the presence of purified GXM. This result suggests that gp120 inhibits translocation of CD40 from the intracellular pool to the cellular periphery. gp120 up-regulates IL-10 secretion [14] . Furthermore, IL-10 is a potent biologic inhibitor of IL-12 secretion [23] , raising the possibility that the presence of gp120 could exacerbate the ability of an encapsulated strain to induce IL-10. Consistent with this hypothesis, gp120 significantly increased IL-10 production by human monocytes stimulated for 18 h with acapsular (7698) or encapsulated (6995) C. neoformans (table 1) .
Our previous study found that gp120 down-regulated IFNg secretion and promoted secretion of IL-4 in response to C. neoformans [11] . In an effort to limit the gp120-induced shift to a Th2-type response, IL-12 was added to our coculture, and the pattern of cytokine response was determined. Two classical cytokines, IFN-g and IL-4, involved in generation of Th1-and Th2-type responses, respectively, were tested. There was a significant increase in IFN-g production by PBMC stimulated with IL-12 alone, as well as by PBMC stimulated with C. neoformans alone (table 2) . Because NK cells expressing IL-12 receptor could be responsible for the appreciable amount of IFN-g produced by PBMC stimulated with IL-12 alone, a subsequent experiment examined cryptococci-laden monocytes plus purified T cells. Incorporation of gp120 into the incubation mixture significantly reduced IFN-g secretion by PBMC and monocytes plus purified T cells in response to encapsulated or acapsular cryptococci or acapsular cryptococci plus GXM (table 2). In contrast, the addition of IL-12 at the time of treatment with gp120 reduced or eliminated the suppressive effect of gp120.
Consistent with our previous report [11] , addition of gp120 to the incubation medium enhanced IL-4 production in response to encapsulated and acapsular C. neoformans (table 3; , gp120-treated cells vs. respective untreated cells). The P ! .05 gp120-enhanced secretion of IL-4 was abrogated by the addition of IL-12 ( , gp120 plus IL-12-treated cells vs. re-P ! .05 spective gp120-treated cells) and was reduced to a level similar to that observed with IL-12 alone.
IL-12Rb2 plays a critical role in controlling the Th1 lineage and in maintaining IL-12 responsiveness [24, 25] . Given that gp120 appears to dampen Th1 in response to C. neoformans, we investigated the possibility that the addition of gp120 could influence IL-12Rb2 expression on T cells cocultured with cryptococci-laden monocytes (6995). The results showed that T cells responding to the encapsulated strain showed appreciable levels 
Discussion
In a recent study, we demonstrated that gp120 alters T cell activation and differentiation in response to C. neoformans and promotes a dominant Th2-type response [11] . The available evidence indicates that development of a Th1-type response is critical in promoting a protective response in C. neoformans infection and that IL-12 plays an important role [26] . On the other hand, an inhibitory effect of gp120 on IL-12 production by monocytes stimulated with Staphylococcus aureus has been observed [14] . In this study, we explored the mechanisms involved in gp120 promotion of a Th2 response to C. neoformans and the possibility of blocking this event.
Recently, we demonstrated that human monocytes treated with C. neoformans produce IL-12 in a T cell-independent and -dependent manner. This latter production is dependent on CD40-CD40 ligand interaction [15] . In the present report, we show that gp120 down-regulates early and late IL-12 secretion by monocytes in response to C. neoformans. This phenomenon paralleled down-regulation of CD40 molecule expression on monocytes, IL-10 up-regulation, and changes in IL-12Rb2 expression on T cells responding to C. neoformans. Furthermore, the ability of gp120 to favor a Th2-type response is blocked by the addition of exogenous recombinant IL-12 such that IFNg secretion in increased and IL-4 secretion is decreased.
gp120 from a T cell-tropic HIV strain was used in our study, and different results might have occurred with gp120 from a monotropic HIV strain. However, the ability of gp120 to bind to a coreceptor such as CXCR4 or CCR5 may not be relevant to our studies, because monoclonal antibody to CD4 blocks the effects of gp120.
Recently we observed that gp120 promotes Th2 generation in response to C. neoformans by inhibiting IFN-g production, as well as by promoting IL-4 [11] . IL-12 plays a key role in induction of the Th1 response [12] . Consequently, the capability of gp120 to inhibit IL-12 secretion may explain, at least in part, the failure of Th1 growth and differentiation.
IL-12 is secreted in a biphasic pattern in response to C. neoformans. Early secretion is induced directly by C. neoformans, and late secretion requires the presence of IFN-g and ligation of CD40 molecules on monocytes [15] . gp120 affects both early and late induction of IL-12. The inhibition of early IL-12 production may be due to gp120 interference with internalization or processing of C. neoformans. This is consistent with previous 2 ϫ 10 target ratio of 1:2. IL-4 was determined in supernatants after 7 days of incubation. Glucuronoxylomannan (GXM) was used at a concentration of 250 mg/mL. a (gp120 plus IL-12-treated vs. respective gp120-treated cells).
observations showing that gp120 affects killing of fungi by monocytes/macrophages [16, 27] . This mechanism may be involved in regulating CD40 expression, which in turn may be responsible for IFN-g reduction. This is supported by the observation that the inhibition of CD40 interaction with CD40 ligand greatly regulated IFN-g production [15] . The increase in CD40 induced by free GXM was unexpected, because GXM induces IL-10 secretion. However, the presence of IL-10 is not necessarily related to CD40 dysregulation on accessory cells [28] .
Our results suggest that the decrease in CD40 on the surface of antigen-presenting cells is a consequence of gp120-mediated inhibition of CD40 translocation from the intracellular pool to the cellular periphery rather than inhibition or degradation of mRNA transcripts. One interpretation of these data is that, by regulating CD40, gp120 could act at the antigen-presenting cell level by possibly inhibiting several CD40-mediated positive signals, such as cytokine release and antimicrobial activity [28] . This is supported by our recent observation that CD40 ligation is involved in promoting the antifungal activity of macrophages [29] .
At present, IL-10 is the best-studied inhibitor of IL-12 production by phagocytic cells [28] . gp120 has been reported to up-regulate IL-10 in response to S. aureus cowan [14] . We confirm and extend the observed IL-10 up-regulation to C. neoformans. Importantly, we found that gp120 exacerbates the capability of the encapsulated strain to induce IL-10 by monocytes. These data suggest that, in AIDS patients with cryptococcosis, free gp120 may act as an adjunctive immunosuppressive signal.
Expression of IL-12 receptor is necessary to maintain the effect of IL-12 and Th1 lineage commitment [30] . Specific binding of IL-12 to the high-affinity receptor complex composed of 2 subunits, IL-12Rb1 and IL-12Rb2, mediates IL-12 responsiveness [31] . During Th2 differentiation there is a selective loss of IL-12Rb2, suggesting that this receptor may govern the IL-12 biologic response. The underexpression of IL-12Rb2 contributes to the Th2 bias. In contrast, the capacity to mount a Th1-type immune response appears to be regulated by cells expressing IL-12Rb2 [25] . Our observation showing that gp120 produces a decrease in IL-12Rb2 expression appears to be inconsistent with the fact that exogenous IL-12 promotes IFNg release. However IL-12 per se is able to up-regulate IL-12Rb2 on T cells [32] . In our experimental system, the addition of exogenous IL-12 at the time of culture preparation could counterbalance the negative effect of gp120-induced IL-12Rb2 expression. This is the first suggestion that C. neoformans promotes a differentiation in Th1 cells through promotion of the IL-12Rb2 chain. This is conceivable, given that the Th1 response has been considered to be protective against C. neoformans [26] and that a protective immune response likely occurs in the immunocompetent host. gp120, in combination with encapsulated C. neoformans, inhibits IL-12Rb2 expression on T cells responding to C. neoformans, providing additional evi- dence that gp120 blocks Th1 development. This may be due to the ability of gp120 to induce IL-10 overproduction [14] , which has been shown to down-regulate the IL-12/IL-12Rb2 pathway [24] .
Despite the presence of gp120, induction of a Th1-type response to C. neoformans will occur if exogenous IL-12 is added to the system. The significant increase in IFN-g production by T cells responding to C. neoformans, coupled with an associated inhibition of IL-4 secretion when IL-12 is added to the system, suggests that the gp120-induced suppression of the response to C. neoformans is reversible and may be corrected with appropriate intervention. It should be considered that exogenous IL-12 may counteract gp120-mediated inhibition of a T cellindependent mechanism inducing early IL-12 secretion by antigen-presenting cells, consistent with IL-12 receptor expression on antigen-presenting cells [33] .
It is possible that free gp120 in AIDS patients with cryptococcosis may facilitate the spread of infection by contributing to suppression of a protective immune response. Hence, scavengers of free gp120, as well as immunopotentiating agents able to counterbalance the deleterious effects of gp120, might offer prospects for control of C. neoformans infection in AIDS patients.
